FIELD: medicine.
SUBSTANCE: invention represents a synergetic combination of (1) antibody specific to CD38 containing HCDR1 section with SYYMN sequence (SEQ ID NO: 14) or GFTFSSYYMN (SEQ ID NO: 1), HCDR2 section with GISGDPSNTYYADSVKG sequence (SEQ ID NO: 2), HCDR3 section with DLPLVYTGFAY sequence (SEQ ID NO: 3), LCDR1 section with SGDNLRHYYVY sequence (SEQ ID NO: 4), LCDR2 section with GDSKRPS sequence (SEQ ID NO: 5) and LCDR3 section with QTYTGGASL sequence (SEQ ID NO: 6), and (2) lenalidomide, pomalidomide or bortezomib, for use in treating multiple myeloma and/or non-Hodgkin lymphoma.
EFFECT: invention is effective in treating said tumour diseases.
17 cl, 20 dwg, 21 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATIONS AND THEIR APPLICATION | 2013 |
|
RU2650618C2 |
| AGENT FOR TREATING MULTIPLE MYELOMA (MM) | 2016 |
|
RU2723047C2 |
| COMPOSITIONS COMPRISING ANTIBODY TO CD38 AND CARFILZOMIB | 2014 |
|
RU2670127C2 |
| COMPOSITIONS COMPRISING CD38 ANTIBODIES AND CARFILZOMIB | 2014 |
|
RU2723937C2 |
| COMPOSITIONS CONTAINING ANTIBODIES TO CD38 AND LENALIDOMIDE | 2013 |
|
RU2698911C2 |
| COMBINATION CANCER THERAPIES TARGETTING CD38 AND TGF-BETA | 2019 |
|
RU2808632C2 |
| ANTIBODIES TO CD38 AND PHARMACEUTICAL COMPOSITIONS BASED THEREON FOR TREATMENT OF AUTOIMMUNE DISEASE MEDIATED BY AUTOANTIBODIES | 2020 |
|
RU2809565C2 |
| NEW SYNERGETIC EFFECTS | 2009 |
|
RU2471499C2 |
| METHOD OF TREATING MULTIPLE MYELOMA | 2009 |
|
RU2519750C2 |
| APPLICATIONS OF IMMUNOCONJUGATES WITH CD138 AS TARGET | 2010 |
|
RU2561041C2 |
